Thyroid Disorders

>

Latest News

FDA Approves Palopegteriparatide for Hypoparathyroidism | Image Credit: US Food and Drug Administration
FDA Approves Palopegteriparatide for Hypoparathyroidism

August 12th 2024

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

Endocrinology Month in Review: May 2024 thumbnail featuring HCOLive endocrinology logo
Endocrinology Month in Review: May 2024

June 4th 2024

US FDA logo in Black over a White Background. | Credit: US Food and Drug Administration
FDA Extends Review for TransCon PTH in Hypoparathyroidism to August 2024

May 14th 2024

Elizabeth Pearce, MD, MSc | Credit: Boston Medical Center
Thyroidectomy, Radioactive Iodine Could Prevent More CV Events than Antithyroid Drugs

March 6th 2024

Endocrinology Month in Review: December 2023 | By HCPLive Endocrinology
Endocrinology Month in Review: December 2023

January 4th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.